A Phase 2/3 interventional study of IMU-838 and Placebo in COVID-19, sponsored by Immunic AG. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-13.
Sponsored by Immunic AG · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in COVID-19 with a site in Bulgaria — 5 open to participants now, 5 under way, 5 of them phase 3. COVID-19 · Bulgaria.
Among the 27 studies in COVID-19 with a site in Bulgaria, this one is the 14th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2020, is one of 6 in phase 2/3, and was the 2nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →5 of the 27 studies in COVID-19 with a site in Bulgaria are open now. Recruiting first, the newest first:
Shionogi · Sites in Bulgaria, United States, Japan
Ages 12+
Pfizer · Sites in Bulgaria, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Bulgaria, United States, Argentina and 21 more countries
Ages 18+
AstraZeneca · Sites in Bulgaria, United States, Argentina and 36 more countries
Ages 18+
Pfizer · Sites in Bulgaria, United States, Japan and 4 more countries
Ages 0–17
A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 14 · Phase 4 1
First in 2020; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 290 across the 25 interventional studies, 3,834 across the 2 observational. Of the 20 that completed or were terminated, 13 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 10 most frequent:
Immunic AG is the lead sponsor of 7 studies on the registry; none are open to participants now.
Immunic AG has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies in COVID-19 with a site in Bulgaria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in COVID-19 with a site in Bulgaria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
At present there is no approved drug treatment for Covid-19. In this study we plan to investigate if an experimental drug called IMU-838 (vidofludimus calcium) can improve your symptoms, prevent worsening that would initiate further treatments such as ventilation, and can lower your virus number if given in addition to your doctor's choice of standard therapy. We will also test if IMU-838 has any side effects and measure the level of IMU 838 in your blood.
Experimental drug means that it is not yet authorized for marketing in your country. To date approximately 600 individuals have received IMU-838 (or a drug similar to IMU-838 that contains the same active substance as IMU-838) in research studies.
The trial consists of a Phase 2 proof-of-concept phase (Part 1) with the option to extend enrollment (without interruption) to Phase 3 (Expansion Phase, Part 2).
This trial is a multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to evaluate the safety and efficacy of IMU-838 as addition to investigator's choice of SoC treatment in patients with COVID-19. Eligible patients will be centrally randomized 1:1 to twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC) or placebo (+ SoC). Randomization will be stratified by age (\< or >=65 years) and antiviral therapy (no antivirals, Hydroxychloroquine and Chloroquine, all other antivirals).
Adaptive sequential trial design and overall trial design
The trial uses an adaptive sequential design. An IDMC will review unblinded data and provide the Sponsor with recommendations regarding modifications of sample size and trial conduct.
A 1st interim analysis (IA1) will be performed after approximately 200 patients have completed the trial (either as scheduled or prematurely), while enrollment continues. If no activity of IMU 838 is observed by the IDMC in this IA, further patient enrollment will be stopped, and a final analysis of Part 1 will be performed (FA1). It is expected that the final analysis of Part 1 will include approximately 230 patients. If the IA1 results indicate activity of IMU-838 in COVID-19, the trial may be extended to Part 2 with a revised sample size derived by the IDMC based on IA1 results and with possible other trial adjustments. If the trial is extended into Part 2, a 2nd IA (IA2) is planned after approximately two-thirds of patients (based on the overall global sample size [Part 1 and Part 2 combined]) have been enrolled to potentially adjust sample size and other trial features if needed. The final analysis of the trial (FA2) will then be done after all patients have completed Part 2.
In addition, an early interim safety analysis will be performed and evaluated by the IDMC after 30 patients have been enrolled to assess unblinded safety data. Further safety analyses can be initiated at any time by the IDMC or Sponsor when new safety signals are identified within this or other trials of IMU-838.
Screening
Patients can be screened for a maximum of 2 days (from Day -2 to Day 0) and eligible patients will be randomized on Day 0 and treated with IMP + SoC for 14 days. It is encouraged to screen potential participants immediately at the day of hospitalization (including informed consent, assessment of inclusion/exclusion criteria, screening laboratory tests all done locally, assessment of clinical and blood gas criteria) and randomize patients on the same day (Day 0). To assess eligibility criteria, existing local laboratory values obtained within 48 hours of randomization can also be used, except for testing of positive status of SARS-CoV-2 infection where a 4-day window is allowed.
IMP administration should start as quickly as possible after randomization and first IMP intended to be given in the evening of the screening day (Day 0).
Blinded Treatment period (Day 0 to Day 13) and Day 14 (end-of-treatment)
The first dose of IMP (2 tablets) should always be given on Day 0 (allowed range for first dose: 12:00 noon on Day 0 to 02:00 a.m.). All further IMP doses are 1 tablet each in the morning and evening. Information about the status and patient care are continuously obtained and documented once or twice daily.
After the last IMP dose in the evening of Day 13, the end-of-treatment assessments will be done on Day 14. Blood sampling for IMU-838 trough values must be performed in the morning around the time the morning dose was usually taken by the respective patient. Patients may then continue to receive SoC without any further restrictions on concomitant medications as during the 14-day BT period .
Day 28 Visit (EoS)
The patient should return for the final trial visit on Day 28 (EoS). If IMP is prematurely discontinued for any reason, the EoS visit should always be conducted on Day 28 and no earlier EoS should be performed. If patients withdraw from IMP prematurely, they should be encouraged to allow the EoS visit as part of the follow-up. If the patient dies during the trial, the investigator should indicate that this visit was not performed. However, even if no EoS visit was performed, information about patient status should be reported on the EoS page in the case report form. If the patient refuses any EoS visit or the patient is lost to follow-up, it is permissive in this trial that the investigator contacts the patient, the family of the patient or the referring physician by phone or email to obtain status of life information, or is able to search in registers or publicly available information for such status of life information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Admitted to the hospital or other medical in-patient treatment facility for treatment of COVID-19 The hospitalization needs to be for medical reasons (treatment of COVID-19 disease) and cannot be for social reasons or due to housing insecurity.
For US sites only: If the investigator would commonly hospitalize the patient but for healthcare resource reasons decides to treat the patient in a specially designed out-patient setting, then such patients are also allowed to enter the trial (please note that in this case the patient would be counted as clinical status category 3). The investigator then must assure that the patient has at least a twice daily assessment by qualified trial personnel and all laboratory assessments can be adequately performed as per protocol. The Sponsor reserves the right to discontinue this option via administrative letter if such assurances cannot be met by any site.
Moderate COVID-19 disease defined as fulfilling clinical status category 3 or 4 on the WHO 9-point ordinal scale [21]:
For women of : Application of a highly effective method of (failure rate less than 1% per year when used consistently and correctly) together with a barrier method between trial consent and 30 days after the last intake of the IMP.
Highly effective forms of birth control are those with a failure rate less than 1% per year and include:
Barrier methods of contraception include:
Male patients must agree not to father a child or to donate sperm starting at Screening, throughout the clinical trial and for 30 days after the last intake of the IMP. Male patients must also
Exclusion Criteria:
Underlying disease-related exclusion criteria
Presence of the following laboratory values at screening:
Use of the following concomitant medications is prohibited from Screening to end of treatment with IMP in this trial (up to Day 14) if not indicated otherwise in this protocol:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC)
Drug: IMU-838
twice-daily (BID) oral placebo (+ SoC)
Other: Placebo
Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable). If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube.
Also known as: vidofludimus calcium
Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
Proportion of Patients Without Any Need for INV Until EoS
Number of Participants Stratified as those With and Without the Need for INV Until End-of-study (EoS). For this outcome a worst case approach was used in which patients who were lost to follow-up or who discontinued the trial on or before Day 13 due to any other reason than death and discontinued with a last observed WHO clinical status no lower than that at Screening, and patients who died were considered as patients requiring INV.
Time frame: Throughout the Study (Day 0 to Day 28)
Days in ICU Department
Duration of ICU Treatment Until EoS for Only Patients Who Were Admitted to the ICU During the Trial.
Time frame: Throughout the Study (Day 0 to Day 28 )
All Cause Mortality (ITT Approach)
28-day All-cause Mortality (including lost to follow-up): 'all-cause-mortality' includes all confirmed deaths and patients who discontinued the trial before Day 28 and for whom no outcome (alive or dead) could be determined at EoS; 'actual death' includes only those patients for which a fatal outcome was confirmed by Day 28.
Time frame: Throughout the Study (Day 0 to Day 28 )
Time to Clinical Improvement
Defined as the time from first dose of investigational medicinal product (IMP) to an improvement of at least 2 points on the Modified WHO Ordinal Scale for Clinical Status (Modified WHO Ordinal Scale for Clinical Status), or live discharge from hospital without oxygen supplementation, whichever comes first. The 50% Kaplan-Meier quartile (median) of actual values per treatment arm is provided as outcome of this variable below.
Time frame: Throughout the Study (Day 0 to Day 28)
Days of Hospitalization
Duration of hospitalization (for US sites only: or treatment in special outpatient setting in lieu of hospitalization due to resource restraints)cacy:
Time frame: Throughout the Study (Day 0 to Day 28 )
Patients Free of Renal-replacement Therapy (RRT)* Until EoS
Number of Patients Both for All Patients and Surviving Patients Free of Renal-replacement Therapy (RRT)\* Until EoS
Time frame: Throughout the Study (Day 0 to Day 28 )
Patients Required ECMO Until EoS
Number and Percentage of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)\* until EoS.
Time frame: Throughout the Study (Day 0 to Day 28 )
Patients Free of INV Until Day 14*
Number and persentage of patients free of INV until Day 14\*
Time frame: Throughout the Study (Day 0 to Day 14 )
Patients Free of RRT
Percentage of patients free of RRT until Day 14\*
Time frame: Day 0 to Day 14
Number of Patients Free of ECMO
Number of patients free of ECMO until Day 14.
Time frame: Day 0 to Day 14
Patients With Improvement of at Least 2 Points (From Randomization) on the 9-category WHO Ordinal scale1
Numbers of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1( Modified WHO Ordinal Scale for Clinical Status)on Days 6, 14, and 28, where score 0 means no clinical or virological evidence of infection and score 8 is the worth outcome ( mens death).
Time frame: on Days 6, 14, and 28
Patients With Auxiliary Oxygen Therapy (Including All Types of Oxygen Therapy)
Percentage of Patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28.
Time frame: on Days 6, 14, and 28
Patients With Clinical Recovery
Percentage of Patients With Clinical Recovery: Axillary Temp \<= 36.6 °C, or Oral Temp \<= 37.2 °C, or Rectal or Tympanic Temp \<= 37.8 °C and Respiratory Frequency \<= 24 Times/Min Without O2 Inhalation and O2 Saturation \>= 98% Without O2 Inhalation
Time frame: Throughout the Study (Day 0 to Day 28 )
Patients With Clinical Recovery
Percentage of Patients With Clinical Recovery Oxygen Saturation ≥98% Without Oxygen Inhalation
Time frame: Throughout the Study (Day 0 to Day 28 )
Patients With Clinical Improvement or Live Discharge From Hospital Without Oxygen Supplementation
Percentage of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first (Modified WHO Ordinal Scale for Clinical Status, where score 0 - for patient with no clinical or virological evidence of infections, score 9 - the worth scenario- death)
Time frame: Throughout the Study (Day 0 to Day 28 )
Percentage of Participants With WHO Status<=2
Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28
Time frame: on Days 6, 14, and 28
Duration of INV
Duration of INV throughout the study. If no entry on the respective CRF page exists, the duration is set to 0 days for patients who performed Day 28 visit. Patients without Day 28 visit and without any entry on the respective CRF page are excluded from analysis.
Time frame: Throughout the Study (Day 0 to Day 28 )
Days on ECMO
Duration of ECMO in days (duration set to 0 for those who did not require ECMO). No participants required ECMO.
Time frame: Throughout the Study (Day 0 to Day 28)
Days on RRT
Duration of RRT in days (duration set to 0 for those who did not require RRT).No participants required RRT.
Time frame: Throughout the Study (Day 0 to Day 28)
Days of Auxiliary Oxygen Therapy
Duration of auxiliary oxygen therapy (including all types of oxygen therapy)
Time frame: Throughout the Study (Day 0 to Day 28)
Days of Hospitalization
Duration of hospitalization for survivors
Time frame: Throughout the Study (Day 0 to Day 28)
Participants With ICU Admission
Percentage of Participants with ICU Admission at different time point
Time frame: on Days 6, 14, and 28
Probability of Death
Probability of death derived from Kaplan Meier analyses
Time frame: Throughout the Study (Day 0 to Day 28)
Days to INV
Time to first prescription of invasive ventilation (INV). The time to first prescription of INV, only patients with actual INV or prescription for INV are considered.
Time frame: Throughout the Study (Day 0 to Day 28)
Days to RRT
Time to first prescription of RRT
Time frame: Throughout the Study (Day 0 to Day 28)
Days to ECMO
Time to first prescription of ECMO
Time frame: Throughout the Study (Day 0 to Day 28)
Days to INV, RRT and ECMO
Time to first prescription of INV, RRT, and ECMO. The time to first prescription of INV, only patients with actual INV or prescription for INV are considered.
Time frame: Throughout the Study (Day 0 to Day 28)
Probability of ICU Admission
Overall probability of ICU admission derived from Kaplan Meier analyses.
Time frame: Throughout the Study (Day 0 to Day 28)
Cumulative Dose
Cumulative Dose of Vasoactive Therapies and Days With Vasoactive Therapies (Daily Until Day 14)
Time frame: Day 0 to day 14
Time to Clinical Recovery
Time of first assessments of parameters contributing to clinical recovery
Time frame: Throughout the Study (Day 0 to EoS [Day 27 up to Day 42])
Plasma Levels of IMU-838
Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28
Time frame: on Days 0, 1, 2, 3, 6, 14, and 28
Correlation of Trough Levels (Quartiles) to Selected Clinical Outcomes
Kaplan-Meier analyses were used to investigate a potential relationship between trough plasma levels of IMU-838 and time to clinical improvement and time to clinical recovery. Estimates of the clinical outcomes were evaluated separately for patients within each of the four quartiles of IMU-838 trough levels at Day 14.
Time frame: Trough levels at Day 14; Clinical outcome: Day 0 to EoS (EoS = Day 27 up to Day 42)
Number of Participants With Adverse Events (AEs) and Serious AEs
Adverse events (AEs) and serious AEs. AEs-Hypertriglyceridemia,Increased glycosylated hemoglobin, Headache, Thrombocytosis, Hyperglycemia, AEs reported in ≥ 2.0% of patients in any treatment group included anemia, bradycardia, sinus bradycardia, tachycardia, pyrexia, hepatocellular injury, hematuria, hypertension and hypertensive crisis. SAEs- deep vein thrombosis,COVID-19 pneumonia, patient death.
Time frame: Throughout the Study (Day 0 to Day 28)
Vital Signs: Height
Safety Height in centimeters will be recorded without shoes. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.
Time frame: at Baseline
Vital Signs: Weight
Safety Weight in kilograms will be recorded without shoes. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.
Time frame: at Baseline
Vital Signs: Body Temperature (ºC)
Safety Body temperature can be measured axillary, oral, rectal or tympanic, but should be always measured by the same method for a patient. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.
Time frame: at Baseline
Albumin Concentration at Various Time Points
Clinical laboratory parameters: blood chemistry (Albumin concentration at various time points)
Time frame: Throughout the Study (Day 0 to Day 28)
Hematocrit Ratio at Various Time Points
Clinical laboratory parameters: hematology- Hematocrit ratio at various time points
Time frame: Throughout the Study (Day 0 to Day 28)
Urine Creatinine at Various Time Points
Clinical laboratory parameters: urinalysis- Urine creatinine at various time points
Time frame: Throughout the Study (Day 0 to Day 28)
Temperature
Temperature data at different time point.
Time frame: Throughout the Study (Day 0 to Day 28)
D-dimer
Disease markers
Time frame: Throughout the Study (Day 0 to Day 28)
Lactate Dehydrogenase (LDH)
Blood levels of disease markers
Time frame: Throughout the Study (Day 0 to Day 28)
C-reactive Protein
Blood levels of disease markers
Time frame: Throughout the Study (Day 0 to Day 28)
Troponin I
Bood levels of disease markers
Time frame: Throughout the Study (Day 0 to Day 28)
Procalcitonin
Blood levels of disease markers
Time frame: Throughout the Study (Day 0 to Day 28)
Correlation of Time to Clinical Improvement With Quartiles of D-Dimer Blood Levels at Day 6
Kaplan-Meier analyses were used to investigate a potential relationship between blood levels of D-Dimer and time to clinical improvement. Estimates of the clinical outcome were evaluated separately for patients within each of the four quartiles of D-Dimer levels at Day 6.
Time frame: D-Dimer levels at Day 6; Clinical outcome: Day 0 to EoS (EoS = Day 27 up to Day 42)
Changing in Log 10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples at Various Time Points
Virologic markers: Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) Mean Viral Load - log10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples: changing of SARS-CoV-2 Viral Load in patients on Days 6,14,28
Time frame: Throughout the Study (Day 0 to Day 28)
Mean Viral Load - log10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples
Virologic markers :Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Time course of SARS-CoV-2 viral load
Time frame: Throughout the Study (Day 0 to Day 28)
Number of Participants With 2 Consecutive Negative SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction Tests at Least 24 Hours Apart
Virologic markers: Qualitative Virologic Clearance in Spontaneous Sputum and Nasopharyngeal Swab Samples (= 2 Consecutive Negative SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction Tests at Least 24 Hours Apart)
Time frame: Throughout the Study (Day 0 to Day 28)
Rate of Conversion to a Negative SARS-CoV-2 (Qualitative) Test
Virologic markers: conversion to a negative SARS-CoV-2 (qualitative) test on Day 28.
Time frame: on Day 28
Time to Conversion to a Negative SARS-CoV-2 (Qualitative) Test
Virologic markers : Time to Conversion to a Negative SARS-CoV-2 (Qualitative) Test Throughout the study. Only patients with viral load measured from nasopharyngeal swab and results provided by the central laboratory (Covance) were included.Conversion to a negative SARS-CoV-2 status is only assumed if a negative test is confirmed by all available subsequent assessments. This means for Day 28/early termination visit no confirmation is needed. If no conversion to a negative status is documented, patients will be censored for survival analysis at the time of the last documented positive test result.
Time frame: Throughout the Study (Day 0 to Day 28)
Interleukin (IL)-17
The profiles of immune system biomarkers
Time frame: Day 0, 6, 14 and Day 28
Interleukin (IL)-1ß
The profiles of immune system biomarkers
Time frame: Day 0, 6, 14 and Day 28
Interleukin (IL)-6
The profiles of immune system biomarkers
Time frame: Day 0, 6, 14 and 28
Interferon Gamma (IFNγ)
The profiles of immune system biomarkers
Time frame: Day 0, 6, 14 and 28
Tumor Necrosis Factor Alpha
The profiles of immune system biomarkers
Time frame: Day 0, 6, 14 and 28
Immunoglobulin (Ig)A and/or IgG Antibodies Against SARS-CoV-2
Proportion of patients with IgA and/or IgG antibodies against SARS-CoV-2on at different time point
Time frame: Day 6, 14 and 28
| Milestone | IMU-838 | Placebo |
|---|---|---|
| Started | 110 | 110 |
| Completed | 93 | 97 |
| Not completed | 17 | 13 |
Number of Participants Stratified as those With and Without the Need for INV Until End-of-study (EoS). For this outcome a worst case approach was used in which patients who were lost to follow-up or who discontinued the trial on or before Day 13 due to any other reason than death and discontinued with a last observed WHO clinical status no lower than that at Screening, and patients who died were considered as patients requiring INV.
| Participants | IMU-838 | Placebo |
|---|---|---|
| No INV needed | 98 | 101 |
| INV needed | 12 | 9 |
Duration of ICU Treatment Until EoS for Only Patients Who Were Admitted to the ICU During the Trial.
| days | IMU-838 | Placebo |
|---|---|---|
| Days in ICU Department | 2.54 ± 7.24 | 2.33 ± 7.24 |
28-day All-cause Mortality (including lost to follow-up): 'all-cause-mortality' includes all confirmed deaths and patients who discontinued the trial before Day 28 and for whom no outcome (alive or dead) could be determined at EoS; 'actual death' includes only those patients for which a fatal outcome was confirmed by Day 28.
| Participants | IMU-838 | Placebo |
|---|---|---|
| actual death | 2 | 2 |
| 28 days all cause mortality (including lost to follow-up) | 9 | 8 |
Defined as the time from first dose of investigational medicinal product (IMP) to an improvement of at least 2 points on the Modified WHO Ordinal Scale for Clinical Status (Modified WHO Ordinal Scale for Clinical Status), or live discharge from hospital without oxygen supplementation, whichever comes first. The 50% Kaplan-Meier quartile (median) of actual values per treatment arm is provided as outcome of this variable below.
| days | IMU-838 | Placebo |
|---|---|---|
| Time to Clinical Improvement | 13.70 (13.70 to 13.80) | 13.80 (13.70 to 13.80) |
Duration of hospitalization (for US sites only: or treatment in special outpatient setting in lieu of hospitalization due to resource restraints)cacy:
| days | IMU-838 | Placebo |
|---|---|---|
| Days of Hospitalization | 13.49 ± 7.00 | 14.35 ± 7.71 |
Number of Patients Both for All Patients and Surviving Patients Free of Renal-replacement Therapy (RRT)\* Until EoS
| Participants | IMU-838 | Placebo |
|---|---|---|
| Patients Free of Renal-replacement Therapy (RRT)* Until EoS | 110 | 110 |
Number and Percentage of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)\* until EoS.
| Participants | IMU-838 | Placebo |
|---|---|---|
| Patients Required ECMO Until EoS | 0 | 0 |
Number and persentage of patients free of INV until Day 14\*
| Participants | IMU-838 | Placebo |
|---|---|---|
| Patients Free of INV Until Day 14* | 102 | 99 |
Percentage of patients free of RRT until Day 14\*
| Participants | IMU-838 | Placebo |
|---|---|---|
| Patients Free of RRT | 110 | 110 |
Number of patients free of ECMO until Day 14.
| Participants | IMU-838 | Placebo |
|---|---|---|
| Number of Patients Free of ECMO | 110 | 110 |
Numbers of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1( Modified WHO Ordinal Scale for Clinical Status)on Days 6, 14, and 28, where score 0 means no clinical or virological evidence of infection and score 8 is the worth outcome ( mens death).
| participants | IMU-838 | Placebo |
|---|---|---|
| Day 6 | 5 | 5 |
| Day 14 | 44 | 39 |
| Day 28 | 95 | 93 |
Percentage of Patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28.
| percentage of participants | IMU-838 | Placebo |
|---|---|---|
| Day 6 | 47.2 | 40.7 |
| Day 14 | 47.7 | 41.1 |
| Day 28 | 48.1 | 42.1 |
Percentage of Patients With Clinical Recovery: Axillary Temp \<= 36.6 °C, or Oral Temp \<= 37.2 °C, or Rectal or Tympanic Temp \<= 37.8 °C and Respiratory Frequency \<= 24 Times/Min Without O2 Inhalation and O2 Saturation \>= 98% Without O2 Inhalation
| percent of patients | IMU-838 | Placebo |
|---|---|---|
| Baseline | 3.7 | 3.6 |
| Day 0 | 5.5 | 3.7 |
| Day 7 | 17.4 | 12.0 |
| Day 10 | 21.7 | 19.5 |
| Day 14 | 40.2 | 45.8 |
| Day 28 | 69.3 | 65.6 |
Percentage of Patients With Clinical Recovery Oxygen Saturation ≥98% Without Oxygen Inhalation
| percent of patients | IMU-838 | Placebo |
|---|---|---|
| Day 7 | 17.4 | 12.0 |
| Day 14 | 40.2 | 45.8 |
| Day 28 | 69.3 | 65.6 |
Percentage of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first (Modified WHO Ordinal Scale for Clinical Status, where score 0 - for patient with no clinical or virological evidence of infections, score 9 - the worth scenario- death)
| percent of patients | IMU-838 | Placebo |
|---|---|---|
| Patients With Clinical Improvement or Live Discharge From Hospital Without Oxygen Supplementation | 91.7 | 88.2 |
Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28
| percentage of patients, WHO status <=2 | IMU-838 | Placebo |
|---|---|---|
| Day 6 | 6.3 | 5.1 |
| Day 14 | 48.5 | 44.3 |
| Day 28 | 97.9 | 96.9 |
Duration of INV throughout the study. If no entry on the respective CRF page exists, the duration is set to 0 days for patients who performed Day 28 visit. Patients without Day 28 visit and without any entry on the respective CRF page are excluded from analysis.
| days | IMU-838 | Placebo |
|---|---|---|
| Duration of INV | 0.00 (0 to 0.1) | 0.07 (0 to 7.0) |
Duration of ECMO in days (duration set to 0 for those who did not require ECMO). No participants required ECMO.
| days | IMU-838 | Placebo |
|---|---|---|
| Days on ECMO | 0 | 0 |
Duration of RRT in days (duration set to 0 for those who did not require RRT).No participants required RRT.
| days | IMU-838 | Placebo |
|---|---|---|
| Days on RRT | 0 | 0 |
Duration of auxiliary oxygen therapy (including all types of oxygen therapy)
| days | IMU-838 | Placebo |
|---|---|---|
| Days of Auxiliary Oxygen Therapy | 4.49 ± 7.01 | 3.86 ± 7.26 |
Duration of hospitalization for survivors
| days | IMU-838 | Placebo |
|---|---|---|
| Days of Hospitalization | 13.53 (6.90 to 15.90) | 14.52 (7.30 to 19.00) |
Percentage of Participants with ICU Admission at different time point
| percent of patients | IMU-838 | Placebo |
|---|---|---|
| Day 6 | 3.7 | 3.8 |
| Day 14 | 3.8 | 5.0 |
| Day 28 | 4.0 | 5.0 |
Probability of death derived from Kaplan Meier analyses
| Probability | IMU-838 | Placebo |
|---|---|---|
| Probability of Death | 0.019 | 0.019 |
Time to first prescription of invasive ventilation (INV). The time to first prescription of INV, only patients with actual INV or prescription for INV are considered.
| days | IMU-838 | Placebo |
|---|---|---|
| Days to INV | 13.8 (13.8 to 13.8) | 6.0 (6.0 to 6.0) |
Time to first prescription of RRT
No measurements were reported for this outcome.
Time to first prescription of ECMO
No measurements were reported for this outcome.
Time to first prescription of INV, RRT, and ECMO. The time to first prescription of INV, only patients with actual INV or prescription for INV are considered.
| days | IMU-838 | Placebo |
|---|---|---|
| Days to INV, RRT and ECMO | 13.8 (13.8 to 13.8) | 6.0 (6.0 to 6.0) |
Overall probability of ICU admission derived from Kaplan Meier analyses.
| Probability | IMU-838 | Placebo |
|---|---|---|
| Probability of ICU Admission | 0.037 | 0.047 |
Cumulative Dose of Vasoactive Therapies and Days With Vasoactive Therapies (Daily Until Day 14)
| mg | IMU-838 |
|---|---|
| Cumulative Dose | 0 |
Time of first assessments of parameters contributing to clinical recovery
| days | IMU-838 | Placebo |
|---|---|---|
| Time to Clinical Recovery | 14.10 (12.90 to 27.80) | 14.10 (13.70 to 27.90) |
Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28
| ug/mL | IMU-838 |
|---|---|
| Baseline | 0.1108 ± 0.1135 |
| Day 1 | 2.9234 ± 1.1493 |
| Day 2 | 3.5724 ± 1.6299 |
| Day 3 | 3.8572 ± 1.8606 |
| Day 6 | 4.3607 ± 2.4872 |
| Day 14 | 4.6514 ± 2.6506 |
| Day 28 | 0.1014 ± 0.0093 |
Kaplan-Meier analyses were used to investigate a potential relationship between trough plasma levels of IMU-838 and time to clinical improvement and time to clinical recovery. Estimates of the clinical outcomes were evaluated separately for patients within each of the four quartiles of IMU-838 trough levels at Day 14.
| days | IMU-838 |
|---|---|
| Time to clinical recovery - Q1 (Min to 3.1 µg/mL IMU-838) | 27.8 (13.2 to 29.1) |
| Time to clinical recovery - Q2 (3.1 to 4.2 µg/mL IMU-838) | 27.9 (12.9 to 28.8) |
| Time to clinical recovery - Q3 (4.2 to 6.0 µg/mL IMU-838) | 11.8 (6.0 to 13.7) |
| Time to clinical recovery - Q4 (6.0 µg/mL to Max IMU-838) | 11.3 (4.8 to 14.1) |
| Time to clinical improvement - Q1 (Min to 3.1 µg/mL IMU-838) | 13.7 (13.7 to 14.0) |
| Time to clinical improvement - Q2 (3.1 to 4.2 µg/mL IMU-838) | 13.8 (13.7 to 14.8) |
| Time to clinical improvement - Q3 (4.2 to 6.0 µg/mL IMU-838) | 13.7 (13.1 to 13.8) |
| Time to clinical improvement - Q4 (6.0 µg/mL to Max IMU-838) | 13.7 (11.0 to 13.9) |
Adverse events (AEs) and serious AEs. AEs-Hypertriglyceridemia,Increased glycosylated hemoglobin, Headache, Thrombocytosis, Hyperglycemia, AEs reported in ≥ 2.0% of patients in any treatment group included anemia, bradycardia, sinus bradycardia, tachycardia, pyrexia, hepatocellular injury, hematuria, hypertension and hypertensive crisis. SAEs- deep vein thrombosis,COVID-19 pneumonia, patient death.
| Participants | IMU-838 | Placebo |
|---|---|---|
| Any AE | 81 | 69 |
| Any serious AE | 2 | 4 |
Safety Height in centimeters will be recorded without shoes. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.
| centimeters | IMU-838 | Placebo |
|---|---|---|
| Male | 178.1 ± 5.7 | 175.6 ± 6.8 |
| Female | 163.0 ± 5.5 | 163.9 ± 4.4 |
Safety Weight in kilograms will be recorded without shoes. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.
| kilograms | IMU-838 | Placebo |
|---|---|---|
| Male | 92.98 ± 18.86 | 88.95 ± 14.05 |
| Female | 77.88 ± 14.46 | 74.09 ± 13.89 |
Safety Body temperature can be measured axillary, oral, rectal or tympanic, but should be always measured by the same method for a patient. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.
| degrees Celsius | IMU-838 | Placebo |
|---|---|---|
| Vital Signs: Body Temperature (ºC) | 36.86 ± 0.58 | 36.75 ± 0.53 |
Clinical laboratory parameters: blood chemistry (Albumin concentration at various time points)
| g/L | IMU-838 | Placebo |
|---|---|---|
| Baseline | 39.4 ± 4.4 | 40.2 ± 4.7 |
| Day 6 | 37.9 ± 4.2 | 38.7 ± 4.9 |
| Day 14 | 39.6 ± 4.6 | 40.3 ± 4.6 |
| Day 28 | 44.0 ± 3.7 | 44.0 ± 4.4 |
Clinical laboratory parameters: hematology- Hematocrit ratio at various time points
| ratio | IMU-838 | Placebo |
|---|---|---|
| Baseline | 0.435 ± 0.052 | 0.448 ± 0.053 |
| Day 6 | 0.430 ± 0.059 | 0.443 ± 0.053 |
| Day 14 | 0.435 ± 0.049 | 0.440 ± 0.051 |
| Day 28 | 0.428 ± 0.046 | 0.432 ± 0.052 |
Clinical laboratory parameters: urinalysis- Urine creatinine at various time points
| umol/L | IMU-838 | Placebo |
|---|---|---|
| Baseline | 11368.1 ± 7672.0 | 11303.9 ± 6496.6 |
| Day 6 | 9259.5 ± 5198.1 | 10214.0 ± 6551.3 |
| Day 14 | 8940.8 ± 5771.0 | 10040.1 ± 6399.2 |
| Day 28 | 10498.2 ± 7776.1 | 11589.2 ± 6665.9 |
Temperature data at different time point.
| degrees Celsius | IMU-838 | Placebo |
|---|---|---|
| Baseline | 36.9 ± 0.58 | 36.8 ± 0.53 |
| Day 6 | 36.7 ± 0.33 | 36.5 ± 0.42 |
| Day 14 | 36.4 ± 0.24 | 36.4 ± 0.34 |
| Day 28 | 36.4 ± 0.21 | 36.4 ± 0.34 |
Disease markers
| ng/mL | IMU-838 | Placebo |
|---|---|---|
| Baseline | 529.5 (79 to 19520) | 473.0 (106 to 5647) |
| Day 14 | 348.0 (91 to 19520) | 357.0 (60 to 19520) |
| Day 28 | 343.0 (100 to 19520) | 332.5 (76 to 9076) |
Blood levels of disease markers
| nkat/L | IMU-838 | Placebo |
|---|---|---|
| Baseline | 4176.0 (1900 to 14886) | 4059.0 (1900 to 14886) |
| Day 14 | 3167.0 (1650 to 11302) | 3117.0 (1850 to 10752) |
| Day 28 | 3375.5 (1650 to 7918) | 3267.0 (1650 to 15053) |
Blood levels of disease markers
| nmol/L | IMU-838 | Placebo |
|---|---|---|
| Baseline | 320.4826 (5.7144 to 2682.911) | 245.2430 (5.7144 to 2362.904) |
| Day 14 | 27.61960 (5.7144 to 6328.698) | 20.95280 (5.7144 to 858.1124) |
| Day 28 | 23.81000 (5.7144 to 207.6232) | 16.19080 (5.7144 to 1447.648) |
Bood levels of disease markers
| ug/L | IMU-838 | Placebo |
|---|---|---|
| Baseline | 0.00860 (0.0086 to 0.0904) | 0.00860 (0.0086 to 0.1054) |
| Day 14 | 0.00860 (0.0086 to 0.0812) | 0.00860 (0.0086 to 1.0152) |
| Day 28 | 0.00860 (0.0086 to 0.0542) | 0.00860 (0.0086 to 0.1053) |
Blood levels of disease markers
| ng/mL | IMU-838 | Placebo |
|---|---|---|
| Baseline | 0.0695 (0.020 to 0.513) | 0.0530 (0.020 to 0.568) |
| Day 14 | 0.0410 (0.020 to 2.880) | 0.0340 (0.020 to 0.120) |
| Day 28 | 0.0380 (0.020 to 0.246) | 0.0350 (0.020 to 1.840) |
Kaplan-Meier analyses were used to investigate a potential relationship between blood levels of D-Dimer and time to clinical improvement. Estimates of the clinical outcome were evaluated separately for patients within each of the four quartiles of D-Dimer levels at Day 6.
| days | IMU-838 | Placebo |
|---|---|---|
| Q 1 (Min to 275 ng/mL D-Dimer) | 13.8 (7.6 to 14.8) | 13.8 (13.7 to 13.8) |
| Q 2 (275 to 450 ng/mL D-Dimer) | 13.7 (12.0 to 13.9) | 13.8 (10.8 to 15.8) |
| Q 3 (450 to 731 ng/mL D-Dimer) | 13.8 (13.7 to 14.8) | 13.8 (13.0 to 14.8) |
| Q 4 (731 ng/mL to Max D-Dimer) | 13.7 (12.0 to 14.0) | 13.8 (13.7 to 14.0) |
Virologic markers: Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) Mean Viral Load - log10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples: changing of SARS-CoV-2 Viral Load in patients on Days 6,14,28
| Change in log10 copies | IMU-838 | Placebo |
|---|---|---|
| Day 2 | -10020591.1 ± 38272166.5 | -62534293.5 ± 380490492.5 |
| Day 6 | -12849771.3 ± 49984377.5 | -84355538.5 ± 416667915.1 |
| Day 14 | -13617000.9 ± 51579374.1 | -89534493.9 ± 429884542.5 |
| Day 28 | -15195922.3 ± 54087022.5 | -44774028.6 ± 249373454.1 |
Virologic markers :Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Time course of SARS-CoV-2 viral load
| log10 Copies | IMU-838 | Placebo |
|---|---|---|
| Baseline | 10966569.9 ± 46215130.5 | 75572844.7 ± 389541813.1 |
| Day 6 | 33277.7 ± 168585.9 | 581813.6 ± 3313425.6 |
| Day 14 | 37642.6 ± 281630.2 | 483522.2 ± 3851254.5 |
| Day 28 | 181.6 ± 673.9 | 369.7 ± 2133.1 |
Virologic markers: Qualitative Virologic Clearance in Spontaneous Sputum and Nasopharyngeal Swab Samples (= 2 Consecutive Negative SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction Tests at Least 24 Hours Apart)
| Participants | IMU-838 | Placebo |
|---|---|---|
| Number of Participants With 2 Consecutive Negative SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction Tests at Least 24 Hours Apart | 69 | 77 |
Virologic markers: conversion to a negative SARS-CoV-2 (qualitative) test on Day 28.
| Participants | IMU-838 | Placebo |
|---|---|---|
| Rate of Conversion to a Negative SARS-CoV-2 (Qualitative) Test | 57 | 60 |
Virologic markers : Time to Conversion to a Negative SARS-CoV-2 (Qualitative) Test Throughout the study. Only patients with viral load measured from nasopharyngeal swab and results provided by the central laboratory (Covance) were included.Conversion to a negative SARS-CoV-2 status is only assumed if a negative test is confirmed by all available subsequent assessments. This means for Day 28/early termination visit no confirmation is needed. If no conversion to a negative status is documented, patients will be censored for survival analysis at the time of the last documented positive test result.
| days | IMU-838 | Placebo |
|---|---|---|
| Time to Conversion to a Negative SARS-CoV-2 (Qualitative) Test | 13.8 (12.8 to 14.1) | 14.0 (13.7 to 27.8) |
The profiles of immune system biomarkers
| pg/mL | IMU-838 | Placebo |
|---|---|---|
| Baseline | 5.860 ± 0.000 | 5.860 ± 0.000 |
| Day 6 | 5.860 ± 0.000 | 5.885 ± 0.177 |
| Day 14 | 5.924 ± 0.621 | 5.860 ± 0.000 |
| Day 28 | 5.866 ± 0.058 | 5.892 ± 0.308 |
The profiles of immune system biomarkers
| ng/L | IMU-838 | Placebo |
|---|---|---|
| Baseline | 0.668 ± 0.159 | 0.654 ± 0.032 |
| Day 6 | 1.014 ± 1.865 | 1.100 ± 2.165 |
| Day 14 | 0.976 ± 1.955 | 0.862 ± 0.970 |
| Day 28 | 0.984 ± 2.240 | 0.662 ± 0.076 |
The profiles of immune system biomarkers
| ng/L | IMU-838 | Placebo |
|---|---|---|
| Baseline | 6.217 ± 8.037 | 5.093 ± 6.438 |
| Day 6 | 5.441 ± 14.271 | 8.435 ± 30.854 |
| Day 14 | 7.697 ± 25.514 | 5.536 ± 26.081 |
| Day 28 | 3.437 ± 14.317 | 1.468 ± 1.879 |
The profiles of immune system biomarkers
| pg/mL | IMU-838 | Placebo |
|---|---|---|
| Baseline | 94.364 ± 166.465 | 92.190 ± 153.798 |
| Day 6 | 28.654 ± 90.127 | 24.141 ± 77.850 |
| Day 14 | 10.469 ± 13.224 | 38.192 ± 150.623 |
| Day 28 | 17.013 ± 33.762 | 14.452 ± 21.067 |
The profiles of immune system biomarkers
| ng/L | IMU-838 | Placebo |
|---|---|---|
| Baseline | 3.084 ± 3.314 | 3.310 ± 5.071 |
| Day 6 | 6.617 ± 21.461 | 8.020 ± 18.418 |
| Day 14 | 7.974 ± 18.526 | 12.064 ± 12.064 |
| Day 28 | 4.778 ± 9.293 | 3.717 ± 5.690 |
Proportion of patients with IgA and/or IgG antibodies against SARS-CoV-2on at different time point
| percent of patients | IMU-838 | Placebo |
|---|---|---|
| Day 6 | 86.0 | 83.8 |
| Day 14 | 96.9 | 94.3 |
| Day 28 | 98.3 | 96.9 |
Collected over Adverse event data were collected until Day 60 after randomization. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IMU-838 | 2/110 (1.8%) | 2/110 (1.8%) | 79/110 (71.8%) |
| Placebo | 2/110 (1.8%) | 4/110 (3.6%) | 65/110 (59.1%) |
| Event | IMU-838 | Placebo |
|---|---|---|
| DeathInvestigations | 2/110 | 2/110 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/110 | 1/110 |
| ThrombosisVascular disorders | 0/110 | 1/110 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/110 | 1/110 |
| Event | IMU-838 | Placebo |
|---|---|---|
| HypertriglyceridaemiaMetabolism and nutrition disorders | 23/110 | 13/110 |
| Glycosylated haemoglobin increasedInvestigations | 10/110 | 6/110 |
| HyperglycaemiaMetabolism and nutrition disorders | 5/110 | 8/110 |
| HeadacheNervous system disorders | 8/110 | 5/110 |
| BradycardiaCardiac disorders | 4/110 | 7/110 |
| TachycardiaCardiac disorders | 7/110 | 2/110 |
| Hepatocellular injuryHepatobiliary disorders | 3/110 | 7/110 |
| HaematuriaRenal and urinary disorders | 7/110 | 4/110 |
| AnaemiaBlood and lymphatic system disorders | 4/110 | 6/110 |
| Sinus bradycardiaCardiac disorders | 6/110 | 5/110 |
| Age, Categorical(Participants) | IMU-838 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 83 | 83 | 166 |
| >=65 years | 27 | 27 | 54 |
| Age, Continuous(years) | IMU-838 | Placebo | Total |
|---|---|---|---|
| Mean | 54.5 ± 13.4 | 53.7 ± 14.2 | 54.1 ± 13.8 |
| Sex: Female, Male(Participants) | IMU-838 | Placebo | Total |
|---|---|---|---|
| Female | 55 | 46 | 101 |
| Male | 55 | 64 | 119 |
| Race/Ethnicity, Customized(Participants) | IMU-838 | Placebo | Total |
|---|---|---|---|
| Race — White | 110 | 107 | 217 |
| Race — Asian | 0 | 1 | 1 |
| Race — Black or African American | 0 | 1 | 1 |
| Race — Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2020 to primary completion in Jan 2021, 7 months.
Results were first posted in Nov 2024, 3 years 10 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 7 months is below that.
Counting every sponsor, half of 169 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vidofludimus-calcium
Immunic AG